Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI30%-b-PCL polymeric micelle nanocarriers

Basit Öğe Kaydı
dc.authoridKoçak, Polen/0000-0003-4493-1061
dc.authoridZemheri, Itır Ebru/0000-0003-0247-0332
dc.authoridOzturk, Naile/0000-0002-7617-8433
dc.authoridYILMAZ, ÖZGÜR/0000-0003-3892-2775
dc.authoridBolat, Zeynep Büşra/0000-0002-9216-6336
dc.authoridNezir, Ayca Ece/0000-0001-8229-1865
dc.authoridGulyuz, Sevgi/0000-0002-2576-3085
dc.authorwosidKoçak, Polen/AGG-7399-2022
dc.authorwosidZemheri, Itır Ebru/JRY-6674-2023
dc.authorwosidOzturk, Naile/F-3650-2017
dc.authorwosidYILMAZ, ÖZGÜR/AAG-2472-2021
dc.authorwosidBolat, Zeynep Büşra/ABG-8060-2020
dc.contributor.authorNezir, Ayca Ece
dc.contributor.authorBolat, Zeynep Busra
dc.contributor.authorOzturk, Naile
dc.contributor.authorKocak, Polen
dc.contributor.authorZemheri, Ebru
dc.contributor.authorGulyuz, Sevgi
dc.contributor.authorOzkose, Umut Ugur
dc.date.accessioned2024-08-04T20:54:27Z
dc.date.available2024-08-04T20:54:27Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractProstate cancer is a global disease that negatively affects the quality of life. Although various strategies against prostate cancer have been developed, only a few achieved tumor-specific targeting. Therefore, a special emphasis has been placed on the treatment of cancer using nano-carrier-encapsulated chemotherapeutic agents conjugated with tumor-homing peptides. The targeting strategy coupling the drugs with nanotechnology helps to overcome the most common barriers, such as high toxicity and side effects. Prostate-specific membrane antigen has emerged as a promising target molecule for prostate cancer and shown to be targeted with high affinity by GRFLTGGTGRLLRIS peptide known as peptide 563 (P563). Here, we aimed to assess the in vitro and in vivo targeting efficiency, safety, and efficacy of P563-conjugated, docetaxel (DTX)-loaded polymeric micelle nanoparticles (P563-PEtOx-co-PEI30%-b-PCL-DTX) against prostate cancer. To this end, we analyzed the cytotoxic activity of P563-PEtOx-co-PEI30%-b-PCL and P563-PEtOx-co-PEI30%-b-PCL-DTX by a cell proliferation assay using PNT1A and 22Rv1 cells. We have also determined the targeting selectivity of P563-PEtOx-co-PEI30%-b-PCL-FITC by flow cytometry and assessed the induction of cell death by western blot and TUNEL assays for P563-PEtOx-co-PEI30%-b-PCL-DTX in 22Rv1 cells. To investigate the in vivo efficacy, we administered DTX in the free form or in polymeric micelle nanoparticles to athymic CD-1 nu/nu mice 22Rv1 xenograft models and performed histopathological analyses. Our study showed that targeting prostate cancer with P563-conjugated PEtOx-co-PEI30%-b-PCL polymeric micelles could exert a potent anti-cancer activity with low side effects.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [213M726, 213M728]en_US
dc.description.sponsorshipAcknowledgementsFinancial support from the Scientific and Technological Research Council of Turkey (TUBITAK, grant numbers 213M726 and 213M728) is gratefully acknowledged. All cell culture and animal experiments were conducted at Yeditepe University. We would like to thank Ayla Burcin Asutay and Murat Ozpolat for their technical support on flow cytometer. We also thank Engin Sumer, Ayse Hande Nayman, Halime Ilhan-Siginc, Selen Tiryaki, and Ipek Bedir for their technical support in the in vivo experiments.en_US
dc.identifier.doi10.1007/s00726-023-03292-3
dc.identifier.endpage1037en_US
dc.identifier.issn0939-4451
dc.identifier.issn1438-2199
dc.identifier.issue8en_US
dc.identifier.pmid37318626en_US
dc.identifier.scopus2-s2.0-85162056264en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1023en_US
dc.identifier.urihttps://doi.org/10.1007/s00726-023-03292-3
dc.identifier.urihttps://hdl.handle.net/11616/101413
dc.identifier.volume55en_US
dc.identifier.wosWOS:001006396200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Wienen_US
dc.relation.ispartofAmino Acidsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstate canceren_US
dc.subjectDocetaxelen_US
dc.subjectPolymeric micelleen_US
dc.subjectDrug deliveryen_US
dc.subjectTargeted therapyen_US
dc.subjectPeptide 563en_US
dc.titleTargeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI30%-b-PCL polymeric micelle nanocarriersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu